TABLE 3.

Visual-evoked potentials at 3 and 6 mo among singleton children whose mothers participated in a supplementation trial of 400 mg/d DHA vs. placebo during the second half of pregnancy, by treatment allocation¹

	Placebo	DHA	P2
Three mo	n = 342	n = 337
Age at measurement, d	94.0 ± 5.4	94.4 ± 5.2	0.25
Latency N1, ms	93.9 ± 17.1	94.2 ± 16.3	0.86
Latency P1, ms	126.3 ± 18.3	125.8 ± 17.5	0.72
Amplitude P, μV	8.14 ± 6.04	7.75 ± 5.97	0.40
Latency N3, ms	157.1 ± 24.1	154.8 ± 23.8	0.22
Six mo	n = 410	n = 407
Age at measurement, d	185.5 ± 6.5	185.3 ± 5.9	0.76
Latency N1, ms	91.9 ± 15.1	90.5 ± 14.6	0.19
Latency P1, ms	123.5 ± 14.3	122.7 ± 14.6	0.39
Amplitude P1, μV	11.3 ± 6.9	11.2 ± 7.2	0.86
Latency N3, ms	154.9 ± 20.2	154.2 ± 19.9	0.63

¹Data are mean ± SD. Sample includes all infants measured at that age.

²Significance of difference in means between treatment groups, by test.